Veracyte | VCYT - Cash And Equivalent


Veracyte reported $362.58M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Agenus USD 3.46M 6.08M Sep/2025
Agilent USD 1.76B 31M Dec/2025
Anika Therapeutics USD 57.99M 4.82M Sep/2025
Arrowhead Research USD 201.64M 112.94M Dec/2025
Bruker USD 293.1M 201.1M Sep/2025
Exact Sciences USD 956M 166.96M Dec/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Illumina USD 1.42B 368M Dec/2025
Intrexon USD 9.34M 1.77M Jun/2024
Karyopharm Therapeutics USD 37.67M 1.05M Sep/2025
Laboratory Of America USD 532.3M 65.8M Dec/2025
Ligand Pharmaceuticals USD 664.52M 596.85M Sep/2025
Myriad Genetics USD 145.4M 71M Sep/2025
Rigel Pharmaceuticals USD 48.53M 4.87M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Siemens EUR 14.5B 146M Sep/2025
Sonic Healthcare AUD 645M 25.39M Jun/2024
Thermo Fisher Scientific USD 9.85B 7.87B Dec/2025
Veracyte USD 362.58M 47M Dec/2025
Waters USD 587.83M 128.71M Dec/2025